Recombinant Rabies Virus As Potential Live-viral Vaccines for HIV-1

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2000 Mar 8

PMID 10706640

Citations 52

Authors

M J Schnell

H D Foley

C A SILER

J P McGettigan

B Dietzschold

R J Pomerantz

Affiliations

Soon will be listed here.

Abstract

Recombinant, replication-competent rabies virus (RV) vaccine strain-based vectors were developed expressing HIV type I (HIV-1) envelope glycoprotein (gp160) from both a laboratory-adapted (CXCR4-tropic) and a primary (dual-tropic) HIV-1 isolate. An additional transcription stop/start unit within the RV genome was used to express HIV-1 gp160 in addition to the other RV proteins. The HIV-1 gp160 protein was stably and functionally expressed, as indicated by fusion of human T cell lines after infection with the recombinant RVs. Inoculation of mice with the recombinant RVs expressing HIV-1 gp160 induced a strong humoral response directed against the HIV-1 envelope protein after a single boost with recombinant HIV-1 gp120 protein. Moreover, high neutralization titers up to 1:800 against HIV-1 could be detected in the mouse sera. These data indicate that a live recombinant RV, a rhabdovirus, expressing HIV-1 gp160 may serve as an effective vector for an HIV-1 vaccine.

Citing Articles

Rabies virus as vector for development of vaccine: pros and cons.

Li Y, Zhou H, Li Q, Duan X, Liu F Front Vet Sci. 2024; 11:1475431.

PMID: 39386254 PMC: 11461460. DOI: 10.3389/fvets.2024.1475431.

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

Interleukin-25 enhances humoral immune responses caused by the rabies virus.

Zhang Y, Zhang M, Liao X, Yu Y, Liu Q, Luo Y Virulence. 2022; 13(1):1446-1454.

PMID: 35999776 PMC: 9423819. DOI: 10.1080/21505594.2022.2116146.

Self-replicating vehicles based on negative strand RNA viruses.

Lundstrom K Cancer Gene Ther. 2022; 30(6):771-784.

PMID: 35169298 PMC: 8853047. DOI: 10.1038/s41417-022-00436-7.

Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.

Vrba S, Kirk N, Brisse M, Liang Y, Ly H Vaccines (Basel). 2020; 8(4).

PMID: 33202961 PMC: 7712223. DOI: 10.3390/vaccines8040680.

References

Doms R, Lamb R, Rose J, Helenius A . Folding and assembly of viral membrane proteins. Virology. 1993; 193(2):545-62. DOI: 10.1006/viro.1993.1164. View

Daniel M, Kirchhoff F, Czajak S, Sehgal P, Desrosiers R . Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992; 258(5090):1938-41. DOI: 10.1126/science.1470917. View

Schnell M, Mebatsion T, Conzelmann K . Infectious rabies viruses from cloned cDNA. EMBO J. 1994; 13(18):4195-203. PMC: 395346. DOI: 10.1002/j.1460-2075.1994.tb06739.x. View

Baba T, Jeong Y, Pennick D, Bronson R, Greene M, Ruprecht R . Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 1995; 267(5205):1820-5. DOI: 10.1126/science.7892606. View

Richardson Jr T, Stryjewski B, Broder C, Hoxie J, Mascola J, Earl P . Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol. 1996; 70(2):753-62. PMC: 189876. DOI: 10.1128/JVI.70.2.753-762.1996. View

Kretzschmar E, Peluso R, Schnell M, Whitt M, Rose J . Normal replication of vesicular stomatitis virus without C proteins. Virology. 1996; 216(2):309-16. DOI: 10.1006/viro.1996.0066. View

Mebatsion T, Schnell M, Cox J, Finke S, Conzelmann K . Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A. 1996; 93(14):7310-4. PMC: 38980. DOI: 10.1073/pnas.93.14.7310. View

Tartaglia J, Excler J, Habib R, Limbach K, Meignier B, Plotkin S . Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses. 1998; 14 Suppl 3:S291-8. View

Belshe R, Gorse G, Mulligan M, Evans T, Keefer M, Excler J . Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS. 1999; 12(18):2407-15. DOI: 10.1097/00002030-199818000-00009. View

10.

Buchholz U, Finke S, Conzelmann K . Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. 1998; 73(1):251-9. PMC: 103829. DOI: 10.1128/JVI.73.1.251-259.1999. View

11.

Baba T, Liska V, Khimani A, Ray N, Dailey P, Penninck D . Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med. 1999; 5(2):194-203. DOI: 10.1038/5557. View

12.

Holtzer C, Roland M . The use of combination antiretroviral therapy in HIV-infected patients. Ann Pharmacother. 1999; 33(2):198-209. DOI: 10.1345/aph.18145. View

13.

Finke S, Conzelmann K . Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3' copy-back ambisense rabies virus. J Virol. 1999; 73(5):3818-25. PMC: 104159. DOI: 10.1128/JVI.73.5.3818-3825.1999. View

14.

Bonfanti P, Capetti A, Rizzardini G . HIV disease treatment in the era of HAART. Biomed Pharmacother. 1999; 53(2):93-105. DOI: 10.1016/s0753-3322(99)80066-3. View

15.

Bender B, Rowe C, Taylor S, Wyatt L, Moss B, Small Jr P . Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol. 1996; 70(9):6418-24. PMC: 190672. DOI: 10.1128/JVI.70.9.6418-6424.1996. View

16.

Schnell M, Buonocore L, Kretzschmar E, Johnson E, Rose J . Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A. 1996; 93(21):11359-65. PMC: 38062. DOI: 10.1073/pnas.93.21.11359. View

17.

Parren P, Burton D, Sattentau Q . HIV-1 antibody--debris or virion?. Nat Med. 1997; 3(4):366-7. DOI: 10.1038/nm0497-366d. View

18.

Sicard D, Salmon-Ceron D, Finkielsztejn L . [Search for a HIV vaccine]. Presse Med. 1997; 26(5):248-54. View

19.

Johnson J, Schnell M, Buonocore L, Rose J . Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol. 1997; 71(7):5060-8. PMC: 191739. DOI: 10.1128/JVI.71.7.5060-5068.1997. View

20.

Burton D . A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A. 1997; 94(19):10018-23. PMC: 33768. DOI: 10.1073/pnas.94.19.10018. View